focus -WSS

focus

author：leisure time 2025-09-27 19:37:10 - browse：938

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

knowledge

WSS

DeepMind touts AlphaFold's new skills as protein folding AI models face off

The health care issue Democrats can’t solve: hospital reform

Why Marc Tessier

Coloradans with cystic fibrosis could lose access to Trikafta

Gene therapy’s promise and the high cost of hope

Lung cancer screening guidelines updated for cigarette smokers

leisure time

focus

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Hollywood unions extend contract negotiations for actors

The health care issue Democrats can’t solve: hospital reform

Activists slam private health insurers over coverage restrictions

Reframing the conversation around gain

Malaria cases in Florida and Texas: Here’s what you need to know

Bill would allow buprenorphine prescription for addiction via telehealth

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

knowledge

Why Marc Tessier

Pfizer's RSV vaccine recommended for approval in Europe

Medicare must police algorithms in Medicare Advantage, Dems say

Sarepta Duchenne therapy fails to meet primary endpoint in trial

EMA weighs against approval for Mirati's lung cancer drug

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

knowledge

leisure time

focus

hotspot